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Abstract: Identification of unknown pharmaceutical impurities is an essential part in the drug development process. In the present study, we 
developed and applied liquid chromatography (LC) – solid-phase extraction (SPE) / nuclear magnetic resonance (NMR) methodology with 
cryoprobe for identification and structural characterization of unknown impurities in 3-bromo-5-(trifluoromethyl)aniline. The three main 
impurities were separated and isolated by LC-SPE system. After multiple trapping, isolated impurities were eluted from the SPE cartridges with 
deuterated acetonitrile and one- and two-dimensional homo- and heteronuclear NMR spectra were recorded. The structures of the unknown 
impurities were determined by detailed inspection of NMR spectra and by mass spectrometric (MS) analysis. The results of the present 
preliminary study demonstrated that LC-SPE/NMR can be used for rapid impurity profiling of 3-bromo-5-(trifluoromethyl)aniline. 
 





S impurities define the quality of a chemical entity, 
their unambiguous structure determination is com-
pulsory part of the pharmaceutical development. Impurity 
identification provides understanding of the impurity origin 
and allows better control of the process. Strict regulatory 
guidelines (International Council for Harmonisation of 
technical requirements for registration of pharmaceuticals 
for human use – ICH, Food and Drug Administration – FDA, 
European Medicines Agency – EMA) made identification of 
low-level impurities an imperative. The determination of 
impurities at low levels depends on the analytical 
application used, indicating that no compound will be 
completely pure if technique sensitive enough is 
administered. For active pharmaceutical ingredients (APIs) 
with maximum daily intake less than 2 g, regulatory 
agencies set the limit for unknown, unspecified impurity at 
0.10 % and 0.15 % for known, specified impurities.[1–7] The 
impurities present in API can be process impurities, 
degradation impurities or impurities originating from raw 
materials used in the synthesis.[8–11] 
 The structural elucidation of an unknown impurity is 
a complex procedure. The conventional approach to the 
impurity identification consists of separation of the 
impurity from the main component followed by isolation 
and multiple spectroscopic analysis and/or analysis by 
other standard techniques such as x-ray crystallography 
and mass spectrometry (MS) of the isolated impurity. 
Modern approach to the drug impurity profiling is based on 
the use of hyphenated systems, usually chromatographic 
with spectroscopic and / or spectrometric system.[12–18] One 
of the most efficient and powerful tools for identification of 
compounds in complex mixtures in the pharmaceutical 
industry is the system comprising of liquid chromatography 
(LC), solid phase extraction (SPE) and nuclear magnetic 
resonance spectroscopy (NMR).[19,20] The post-column peak 
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deuterated mobile phases during the chromatographic 
separation and enables the separated compounds to be 
pre-concentrated for subsequent NMR analysis. In 
addition, the use of cryogenically cooled probe for NMR 
measurements further improves the sensitivity of the 
method.[21–24] 
 3-Bromo-5-(trifluoromethyl)aniline is used as a 
building block in pharmaceutical industry. The trifluoro 
moiety can be found in several APIs such as anacetrapib, 
cinalcet, nilotinib, ponatinib and radotinib.[25–29] Due to the 
fact that fluorine atoms can dramatically influence 
molecules’ properties, fluorine has become unavoidable 
atom in drug development.[30] In order to avoid difficult 
fluorination chemistry, it is usually being incorporated in 
the API via fluorine-containing raw material.[31] 
 To the best of our knowledge, no data regarding 3-
bromo-5-(trifluoromethyl)aniline potential impurities are 
available in the literature. The impact of elucidation of 
structures of those impurities benefits both the under-
standing of 3-bromo-5-(trifluoromethyl)aniline synthesis 
and may provide insights into the potential impurities 
found in the related APIs. In the present preliminary 
study, sample of 3-bromo-5-(trifluoromethyl)aniline was 
analysed by ultra high performance liquid chromatog-
raphy (UHPLC) with ultraviolet diode array detection  
(UV-DAD) and results revealed presence of several 
impurities in the range of 0.1–1.5 %. Therefore, we 
developed and applied LC-SPE/NMR methodology with 
cryoprobe for separation, isolation and structural 
characterization of the three main impurities in 3-bromo-
5-(trifluoromethyl)aniline sample. The structures of the 
unknown impurities were determined by recording and 
interpretation of one- and two-dimensional homo- and 




The UHPLC analyses were performed on an Agilent 1290 
Infinity II LC system with a DAD. The UV spectra of all peaks 
were recorded from 190 to 400 nm, and the working 
wavelength was 224 nm. The column used was Waters 
Acquity UPLC BEH C18 (100 mm × 2.1 mm i.d., particle size 
1.7 μm). The column and autosampler temperatures were 
60 °C and 10 °C, respectively. Mobile phases employed for 
gradient elution were water / acetonitrile mixture (95 : 5, v / v) 
as mobile phase A and acetonitrile as mobile phase B. 
Gradient conditions for the analysis were: linear gradient 
from 40 % of mobile phase B up to 60 % of mobile phase B 
from 0 to 1.5 min; isocratic flow at 60 % of mobile phase B 
from 1.5 to 3.0 min; linear gradient up to 95 % of mobile 
phase B from 3.0 to 7.0 min; linear gradient up to 40 % of 
mobile phase B from 7.0 to 8.0 min; and finally, recondi-
tioning the column for 1.5 min on starting conditions. 
Typically, 2 μL of methanol sample solution was injected at 
a flow rate of 0.4 mL min–1. 
 
LC-SPE Analysis 
The LC–SPE analyses were performed on an Agilent 1260 
Infinity HPLC system coupled with Bruker Prospekt2 SPE 
system comprising of make-up flow pump, high pressure 
dispenser, automatic cartridge exchanger module and SPE 
cartridge holder. The UV spectra of all peaks were recorded 
from 190 to 400 nm, and the working wavelength was  
224 nm. The HPLC column used was Waters XBridge C18 
(250 mm × 4.6 mm i.d., particle size 5 μm). The column and 
autosampler temperatures were 50 °C and 15 °C, respec-
tively. Water (mobile phase A) and acetonitrile (mobile 
phase B) were used as mobile phases for gradient elution 
at a flow rate of 1.0 mL min–1. Gradient conditions for the 
analysis were: linear gradient from 32 % of mobile phase B 
up to 67 % of mobile phase B from 0 to 35.0 min; 
reconditioning the column for 5 min on starting conditions. 
In order to increase the retention of the compounds on SPE 
cartridges a post-column water addition was performed 
with a flow rate of 3.0 mL min–1. Injection volume was 
typically 10 μL. Impurities were trapped on HySphere Resin 
GP SPE cartridges (10 mm × 2 mm). 
NMR Spectroscopy 
NMR spectra with NOESY-type solvent suppression module 
were recorded on Bruker Avance III HD 400 NMR 
spectrometer equipped with a broadband observed (BBO) 
5 mm Prodigy cryoprobe and z-gradient accessories. After 
LC separation and analyte trapping on the SPE unit, the 
isolated impurities were dissolved in acetonitrile-d3 and 
measured in 3 mm tubes with MATCH inserts for adapting 
the tubes to 5 mm Bruker spinners. All experiments were 
performed at 298 K. 1H and 13C chemical shifts were 
referenced with respect to tetramethylsilane whereas the 
19F NMR spectra were referenced to CFCl3. 
 1H NMR spectra with spectral width of 8013 Hz and 
a digital resolution of 0.49 Hz per point were measured with 
128 scans. 19F NMR spectra were acquired with 128 scans, 
the spectral width of 150 kHz and digital resolution of  
2.29 Hz per point. The gCOSY spectra were acquired using 
2048 points in the f2 dimension and 256 increments in the 
f1 dimension. For each increment, 16 scans and the spectral 
width of 6394 Hz were applied. Digital resolution was 6.24 
and 49.95 Hz per point in f2 and f1 dimensions, 
respectively. 
 The gHSQC spectra were measured with 64 scans 
and the spectral width of 6394 Hz in f2 and 18112 Hz in f1 
dimension. 2048 points were used in the f2 dimension and 
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6.24 Hz per point in f2 dimension and 141.5 Hz per point in 
f1 dimension. The gHMBC spectra were acquired with 128 
scans and the spectral width of 5330 Hz in f2 and 22346 Hz 
in f1 dimension. 2048 points were used in the f2 dimension 
and 256 increments in the f1 dimension. The resulting 
digital resolution was 5.21 and 174.6 Hz per point in f2 and 
f1 dimensions, respectively. 
UHPLC-MS Analysis 
The LC–MS analyses were performed on a Waters Acquity 
UPLC I-Class system with a photo diode array (PDA) 
detector hyphenated with Waters Acquity single 
quadrupole mass detector (SQD). The column used was 
Waters Acquity UPLC BEH C18 (100 mm × 2.1 mm i.d., 
particle size 1.7 μm). The column and autosampler 
temperatures were 60 °C and 10 °C, respectively. Mobile 
phases employed for gradient elution were water as mobile 
phase A and acetonitrile with addition of formic acid (φ = 
0.02 %) as mobile phase B. Gradient conditions for the 
analysis were: isocratic flow at 33 % of mobile phase B from 
0 to 2.0 min; linear gradient up to 67 % of mobile phase B 
from 2.0 to 8.0 min; change up to 33 % of mobile phase B 
from 8.0 to 8.1 min; and finally, reconditioning the column 
for 1.0 min on starting conditions. Typically, 0.2 μL of 
sample was injected at a flow rate of 0.4 mL min–1. The MS 
spectra were obtained under positive electrospray 
ionisation (ESI), capillary voltage of 1000 V, cone voltage of 
60 V, extractor voltage of 1.00 V, desolvation temperature 
of 200 °C and source temperature of 80 °C. Cone gas flow 
was 50 L h–1 and desolvation gas flow was 550 L h–1. Mass 
range in which the measurements were performed was 
from m / z 80 to 500. 
Chemicals 
Both acetonitrile and methanol gradient grade for 
chromatography were purchased from J. T. Baker. 
Acetonitrile-d3 was purchased from Euriso-top and formic 
acid (98 % p.a.) was purchased from Merck. 
Sample preparation  
3-Bromo-5-(trifluoromethyl)aniline sample was dissolved 
in methanol. Final concentrations were 0.15 mg mL–1 for 
UHPLC and 150 mg mL–1 for LC-SPE analysis. 
 
RESULTS AND DISCUSSION 
Prior to LC-SPE/NMR analysis, chromatographic UHPLC 
method for separation of impurities in 3-bromo-5-
(trifluoromethyl)aniline was developed and optimised with 
regard to the column and gradient elution. The three main 
unknown impurities of 3-bromo-5-(trifluoromethyl)aniline 
were detected by DAD during the UHPLC analysis eluting 
with respect to the main peak at relative retention times of 
1.21 (impurity 1), 1.26 (impurity 2) and 1.31 (impurity 3) 
(Figure 1). 
 As calculated by the peak area normalization 
method, the sample of 3-bromo-5-(trifluoromethyl)aniline 
contained 0.37 %, 0.74 %, and 1.33 % of impurities 1, 2, and 
3, respectively. Comparison of the UV spectra of 3-bromo-
5-(trifluoromethyl)aniline with those of impurities 1–3 
suggested a structural similarity between the compounds. 
Retention times in LC-UV-DAD chromatogram indicated 
lower polarity of the impurities 1–3 when compared to the 
main compound. In order to elucidate the structures of the 
unknown impurities, compounds 1–3 were separated and 
isolated from the sample by LC-SPE system. The chromato-
graphic method was transferred from UHPLC to HPLC by 
changing the column, adjusting the column temperature 
and the mobile phase flow rate. After multiple trapping of 
analysed impurities, performed in order to ensure a suffi-
cient analyte quantity allowing the acquisition of NMR 
spectra with improved signal-to-noise ratio, the analytes 
were eluted from the cartridges to NMR tubes with deuter-
ated acetonitrile. For all three impurities, one-dimensional 
1H and 19F, and two-dimensional COSY, 1H-13C HSQC and  
1H-13C HMBC spectra were recorded. 
 In the 1H NMR spectrum of impurity 1 two singlets 
appeared in the aromatic region (at 7.71 and 7.12 ppm) 
indicating a tetrasubstituted benzene ring with two protons 
in para position to each other (Figure 2a). In addition, a 
broad singlet was observed at 5.18 ppm and assigned to 
protons of the amino group. The 19F NMR spectrum 
displayed a signal at –61.07 ppm attributed to the 
trifluoromethyl group. The analysis of the 1H NMR 
spectrum of impurity 2 revealed two doublets in the 
aromatic region (at 7.18 and 7.15 ppm) corresponding to 
two protons (Figure 2b). The value of coupling constant 
between these two protons was measured to be 2.1 Hz. 
This indicated that impurity 2 contains four substituents on 
benzene ring with two protons in meta position to each 
Figure 1. UHPLC-UV-DAD chromatogram of 3-bromo-5-
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other. A broad singlet at 5.07 ppm which can be attributed 
to protons of the amino group also appeared in the 1H NMR 
spectrum. The 19F NMR spectrum revealed a signal at  
–63.2 ppm assigned to the trifluoromethyl group. The  
1H NMR spectrum of impurity 3 showed two multiplets in 
the aromatic region (at 7.22–7.21 and 7.03–7.02 ppm) 
corresponding to two protons and indicating that impurity 
3 also contains four substituents on benzene ring (Figure 2c). 
Furthermore, the broad singlet at 5.15 ppm was observed 
in the 1H NMR spectrum and attributed to the protons of 
the amino group whereas the 19F NMR spectrum showed a 
signal at –63.76 ppm which can be assigned to the 
trifluoromethyl group. The correlation peaks in 2D COSY 
spectrum of impurity 3 suggested that the two aromatic 
protons are in meta position to each other. Analysis of 
multiplets in the 1H NMR spectrum of impurity 3 indicated 
that the signals of the aromatic protons are split into 
doublets because of meta coupling between them, and 
doublets are further split into quartets due to coupling with 
fluorine atoms of the trifluoromethyl group (the inset in 
Figure 2c). The splitting pattern of aromatic protons in  
1H NMR spectrum of impurity 3 thus confirmed that the 
two protons are adjacent to the trifluoromethyl group. The 
analysis of HSQC spectra of impurities 1–3 enabled 
unambiguous assignment of the protonated carbon atoms 
while the inspection of HMBC spectra revealed information 
about the quaternary carbon atoms. The presented NMR 
data suggested that impurities 1–3 are tetrasubstituted 
benzene derivatives containing amino and triflouromethyl 
groups and the two additional substituents. 
 In order to deduce the complete structures, the so-
lutions of isolated impurities 1–3 were further analysed by 
LC coupled with a single quadrupole mass spectrometer. As 
mobile phases used for LC–UV–DAD analysis of 3-bromo-5-
(trifluoromethyl)aniline contained only water and acetoni-
trile, it was necessary to modify them in order to ensure the 
ionisation of the compounds. Therefore, formic acid was 
used as an additive. LC–MS chromatograms were 
comparable to the chromatograms obtained in the initial 
testing of the 3-bromo-5-(trifluoromethyl)aniline sample. 
Peaks were tracked by comparing the retention times and 
UV spectra of separated components. ESI-MS spectra 
acquired with a UHPLC-UV-DAD-MS hyphenated system 
revealed that all three isolated impurities are isomers. The 
difference from the elemental composition of 3-bromo-5-
(trifluoromethyl)aniline compound was an additional 
bromine atom. This was confirmed by isotope distribution 
characteristic for molecules with two bromine atoms (1 : 2 : 1) 
(Figure 3). The fragmentation that is most likely to occur  
is the observed elimination of one bromine atom (m / z  
318 : 320 : 322 → m / z 238 : 240). 
 The results of LC-MS analysis along with the 
assignment of NMR resonances and inspection of the 
correlation peaks in HMBC spectra (Figure 4) providing 
information on the relative position of the substituents on 
the benzene rings allowed for structural identification of 
 
Figure 2. 1H NMR spectra of impurities (a) 1; (b) 2; and (c) 3
in acetonitrile-d3 recorded in the LC-SPE/NMR mode. The 
inset in c) shows quartet of doublets splitting pattern of 
aromatic protons in 1H NMR spectrum of impurity 3. 
 
 
Figure 3. ESI-MS spectrum of impurity 3. 
 
 
Figure 4. HMBC spectrum of impurity 1 obtained in the LC-
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impurities 1–3. The proposed structures of the three main 
impurities in 3-bromo-5-(trifluoromethyl)aniline are shown 
in Scheme 1. 
 In conclusion, this preliminary study has 
demonstrated that LC-SPE/NMR system with cryoprobe 
can be used successfully for rapid isolation and 
identification of unknown impurities in 3-bromo-5-
(trifluoromethyl)aniline. After the three main impurities 
were separated by LC and trapped on SPE cartridges, one- 
and two-dimensional NMR spectra were recorded. The 
analysis of NMR spectra and results of MS measurements 
suggested that the three main impurities present in 3-
bromo-5-(trifluoromethyl)aniline are di-bromo derivatives 
of 3-(trifluoromethyl)aniline. Studies regarding the 
identification of additional impurities in 3-bromo-5-
(trifluoromethyl)aniline by using LC-SPE/NMR approach are 
in progress in our laboratory. 
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